Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Aug 27 2021 | AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 Industry News Industry Read More Aug 27 2021 | Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Industry News Industry Read More Aug 27 2021 | HFSA Announces Late Breaking Clinical Trials Coming to HFSA 2021 HFSA News Annual Scientific Meeting Read More Aug 19 2021 | US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction Industry News Industry Read More Aug 18 2021 | HFSA President's Update: August 2021 HFSA News President's Updates Read More Pagination First page « First Previous page ‹ Previous … Page 77 Page 78 Page 79 Page 80 Current page 81 Page 82 Page 83 Page 84 Page 85 … Next page Next › Last page Last »
Aug 27 2021 | AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 Industry News Industry Read More
Aug 27 2021 | Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction Industry News Industry Read More
Aug 27 2021 | HFSA Announces Late Breaking Clinical Trials Coming to HFSA 2021 HFSA News Annual Scientific Meeting Read More
Aug 19 2021 | US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction Industry News Industry Read More
